🧬 MSI-H mCRC on ICIs — PD patterns matter • 🔥 31% PD • ⏱️ Early-global <6 mo: OS 7.8 mo • 🕒 Late-global >6 mo: OS 38.8 mo • 🎯 Oligo-PD (<3 mets): OS 97.2 mo • 🩻 Oligo-PD = window for local therapy 🔗 https://t.co/hxdiGvEj17

Resident's Corner- Management of Colorectal Peritoneal Metastases exclusively in #DCRJournal: https://t.co/1YDo0Ihjw9

NCCN Breast Cancer v5.2025 — Key Updates 🔍🎗️ The latest NCCN update continues the shift toward safe de-escalation in localized #BreastCancer : • Axilla SLNB can replace ALND in select patients → less morbidity with no compromise in outcomes. @OncoAlert #bcsm

And proudly, our presentations placed 1st and 3rd this year. Huge credit to the whole team

At the 12th Surgical Research Congress, 2 of the 7 selected oral presentations and 4 of the 10 selected national studies came from Acıbadem General Surgery 🔥🔥

Semaglutide and tirzepatide prescriptions for obesity have increased among patients with preexisting cancer, with notable variation by cancer type and absence of cancer-specific guidelines. https://t.co/upXIWf6cg2

Recurrence Patterns of Esophageal Adenocarcinoma in the ESOPEC Trial Comparing Perioperative CTx With Preoperative Chemoradiotherapy @JCO_ASCO https://t.co/FN6K1rdWeV 👉similar locoregional recurrence 👉less Distant recurrence with FLOT 🧐FLOT improved OS through better systemic

🏥Diagnostic accuracy of radiomics-based AI modes for detecting tumor deposits on MRI in rectal cancer 📽️ https://t.co/Kef1GrQDco Maab Saleh presents her @OPSORE BJS Prize paper from the 26th Annual Meeting of the Egyptian Society of Colon and Rectum Surgeons. #AI #cancer

An honor to meet Prof. Bismuth, a true pioneer in hepatobiliary surgery and a legend whose work continues to inspire us.

In just 3 yrs, Eli Lilly’s tirzepatide overtakes Merck’s Keytruda — $35 B vs $31.8 B est in 2025. The fastest-growing drug ever. From oncology to obesity, the pharma crown shifts to GLP-1s.

👑FORTITUDE-101 Presidential 3 #ESMO25 @myESMO ➡️Bemarituzumab plus FOLFOX in 1L advanved gastric/GEJ adenoca FGFR2b-overexpressing (>10% 2+/3+ tumor cell staining ✅mOS: 17.9vs 12.5 mo HR: 0.61 [0.43, 0.86]; P = 0.005 🤔Longer follow ➡️ loss of benefit ❗️eye toxicity 🤔in PDL1

A dream realized! 🎉 I presented the STELLAR-303 Phase 3 results today at #ESMO2025 — simultaneously published in The Lancet! Trial met its OS primary endpoint in MSS CRC. From CAMILLA to now, 8 years of relentless work. Full circle. A new era begins. Grateful. 🙏✨@OncoAlert

💎 #ESMO25 Presidential Session w/ @JeanneTie #ColorectalCancer – Phase III DYNAMIC-III: ctDNA-guided de-escalation after surgery in stage III colon cancer In ctDNA⁻ patients: ☄️ 3-year RFS 85.3% vs 88.1% (standard) 🎯 Oxaliplatin exposure reduced 88.6% ➜ 34.8% 💥 Fewer

NICHE-2 absolutely delivers. Game over for chemo in dMMR colon cancer 💥🧬 In locally advanced dMMR colon cancer, FOxTROT already showed us chemo doesn’t work, and now NICHE-2 makes it undeniable. 💊 Neoadjuvant nivolumab + ipilimumab → • 99% pathologic response • 67%

PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II CRC patients #ESMO25 #ESMOAmbassadors 👉ctDNA trajectories define prognosis 👉 3yr-DFS: 82 (-) vs 58% (+) 🧐Very innovative trail design, ctDNA guided ACT is the future @myesmo

We have seen the mountain ⛰️ top! MATTERHORN OS #ESMO25 OS continues to ⬆️over time (~7% 3y) Benefit independent of PD-L1 Enough now to adopt as SOC? #ESMOAmbassadors

📢PERISCOPE II Upper GI Mini Oral #ESMO25 ➡️Synchronous peritoneal metastatic gastric ca ➡️3-4 cycle 1L systemic tx, if not progressed and PCI < 7: gastrectomy and CRS/HIPEC vs. contunie 1L ❌Negative, closed premature due to futility ❌No benefit but toxic #cancer #oncology

Holy smokes, MATTERHORN hits OS! 🏔️🔥 We’ve been waiting for this one. After FLOT became standard for resectable gastric and GEJ adenocarcinoma, everyone wondered if adding immunotherapy could move the bar. Earlier this year, MATTERHORN showed a big EFS win for DFLOT, along with

PERISCOPE II trial: Systemic therapy, gastrectomy and CRS/HIPEC vs systemic therapy alone for gastric cancer with limited peritoneal dissemination #ESMO25 #ESMOAmbassadors 👉 mOS: 16.6 vs 15.6 mo 🧐no benefit for CRS/HIPEC for pts with limited peritoneal metastasis, significant

Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial | Nature Medicine @#ESMO25 ⁦@myESMO⁩ ⁦@OncoAlert⁩